NSCLC is a highly active research area and its treatment is rapidly evolving. The algorithm for the treatment of advanced NSCLC has become increasingly complex as new therapies are being developed, including advances in the treatment of patients without targetable activating mutations. Studies evaluating immune checkpoint inhibitors as single agents and in combination with chemotherapy as first-line therapy for patients with advanced NSCLC without targetable activating mutations have been reported. Clinicians need to be familiar with these data and the evolving treatment landscape so they are prepared to optimally select and sequence treatment options for these patients.
Through real-world clinical cases, the expert panel will evaluate the most recent clinical data and provide evidence-based updates and expert insights on the discussion points. Discussion will include immunotherapy and combination regimens for the initial treatment of patients with advanced NSCLC without targetable activating mutations, and how the experts discerned the best treatment approaches based upon unique disease and patient characteristics.